Centre for Prevention and Health Services Research, National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Int J Obes (Lond). 2010 Jun;34(6):1060-9. doi: 10.1038/ijo.2010.2. Epub 2010 Feb 2.
Obesity and physical inactivity are associated with several diseases such as diabetes, cardiovascular diseases, musculoskeletal complaints, osteoporosis, certain types of cancer and depression. However, few data are available on the specific types of medication associated with obesity and physical inactivity.
The aim of this study was to determine the independent association of body mass index (BMI) and physical inactivity with use of specific classes of prescription drugs, and the interaction between BMI and physical inactivity.
The Doetinchem Cohort Study is a population-based longitudinal study. We analyzed cross-sectional data of 1703 men and 1841 women, examined between 1998 and 2002, for whom drug-dispending data were available from the PHARMO database. Drugs were coded according to the WHO Anatomical Therapeutic Chemical (ATC) classification system. Body weight was measured during the physical examination. Physical activity was assessed using an extensive questionnaire. Persons were defined as a user of a certain drug class if they filed at least one prescription in the year around (+/-6 months) the examination.
Compared with normal weight persons (BMI 18.5-25 kg m(-2)), obese persons (BMI>30 kg m(-2)) had a higher use of prescription drugs of several drug classes, especially cardiovascular drugs (OR (95% CI): 3.83 (2.61-5.64) in men and 2.80 (2.03-3.86) in women) and diabetes drugs (OR (95% CI): 5.72 (2.32-14.14) in men and 3.92 (1.80-8.54) in women). In women, physical inactivity was also associated with higher use of certain drug classes, such as drugs for blood and blood-forming organs (OR (95% CI): 2.11 (1.22-3.65)) and musculoskeletal drugs (OR (95% CI): 2.07 (1.45-2.97)), whereas in men this was not the case. We found no interaction between BMI and physical inactivity with respect to use of prescription drugs.
In both men and women, obesity was associated with a higher use of several types of prescription drugs, whereas physical inactivity was only associated with a higher use of certain drug classes in women.
肥胖和身体活动不足与多种疾病有关,如糖尿病、心血管疾病、肌肉骨骼疾病、骨质疏松症、某些类型的癌症和抑郁症。然而,关于与肥胖和身体活动不足相关的具体药物类型的数据较少。
本研究旨在确定体重指数(BMI)和身体活动不足与特定类别的处方药使用之间的独立关联,以及 BMI 和身体活动不足之间的相互作用。
多特丹队列研究是一项基于人群的纵向研究。我们分析了 1703 名男性和 1841 名女性的横断面数据,这些数据是在 1998 年至 2002 年间检查时从 PHARMO 数据库获得的。药物根据世界卫生组织解剖治疗化学(ATC)分类系统进行编码。在体检期间测量体重。身体活动使用广泛的问卷进行评估。如果某人在检查前后的一年左右(+/-6 个月)内开了至少一种处方,则将其定义为某种药物类别的使用者。
与正常体重者(BMI 18.5-25 kg/m²)相比,肥胖者(BMI>30 kg/m²)使用了几种药物类别的处方药,尤其是心血管药物(男性 OR(95%CI):3.83(2.61-5.64)和女性 OR(95%CI):2.80(2.03-3.86))和糖尿病药物(男性 OR(95%CI):5.72(2.32-14.14)和女性 OR(95%CI):3.92(1.80-8.54))。在女性中,身体活动不足也与某些药物类别的使用增加有关,如血液和造血器官药物(OR(95%CI):2.11(1.22-3.65))和肌肉骨骼药物(OR(95%CI):2.07(1.45-2.97)),而在男性中则不是这样。我们没有发现 BMI 和身体活动不足与处方药使用之间存在交互作用。
在男性和女性中,肥胖与多种类型的处方药使用增加有关,而身体活动不足仅与女性中某些药物类别的使用增加有关。